Skip to main content
. 2019 Dec 2;8(1):27–33. doi: 10.1016/j.prnil.2019.10.005

Fig. 2.

Fig. 2

Kaplan–Meier analysis for the time to prostate-specific antigen progression-free survival (A) and overall survival (B) in the total population (n = 55).